Major sponsorship is provided by the Texas State EnergyConservation Office

Major sponsorship is provided by the Texas State EnergyConservation Office. is a privately-held specialtypharmaceutical company headquartered in San Diego, California that is focused onacquiring, developing and marketing products to treat pain and relatedconditions. Victory markets its lead product, NAPRELAN® (naproxen sodium)Controlled-Release Tablets and other pain products to pain managementspecialists, rheumatologists, orthopedic surgeons and selected primary carephysicians through its physician office-based field sales force. Furtherinformation regarding Victory Pharma is available at NAPRELAN® is a trademark of Elan Corporation, plc.

Forward-Looking StatementsThis announcement contains forward-looking statements. Company Name:Shionogi & Co., Ltd.Representative:Isao Teshirogi, President Securities Code: 4507; TSE 1st Section / OSE 1st Section For Inquiries, Contact:Noriyuki Kishida, General Manager, Corporate Communications Dept Telephone: +81 - (6) 6202-2161Sciele Pharma, Inc.Joseph T. The Company`s success is basedon placing the needs of patients first, improving health and quality of life,and implementing its business platform - an Entrepreneurial Spirit, Innovation,Execution Excellence, Simplicity, and Teamwork. For more information on Sciele,please visit On October 9, 2008, Shionogi & Co., Ltd.

and Sciele Pharma announced thecompletion of Shionogi`s acquisition of Sciele. Sciele is now an indirect whollyowned subsidiary of Shionogi. About Shionogi & Co., Ltd.Shionogi & Co., Ltd., headquartered in Osaka, Japan, is a major research-drivenpharmaceutical company dedicated to placing the highest value on patients.Shionogi`s Research and Development currently targets three therapeutic areas:Infectious Diseases, Pain, and Metabolic Syndrome. The Company`s Cardiovascular and Diabetes products treatpatients with high cholesterol, hypertension, high triglycerides, unstableangina and type 2 diabetes; its Women`s Health products are designed to improvethe health and well-being of women and mothers and their babies; and itsPediatrics products treat allergies, asthma and attention deficit andhyperactivity disorder (ADHD).

Founded in 1992 and headquartered in Atlanta,Georgia, Sciele employs more than 1,000 people. (Head Office: San Diego, California, USA;President and CEO: Matt Heck; hereafter "Victory"), today announced that Scieleand Victory Pharma, Inc. have mutually agreed to terminate their previouslyannounced merger agreement due to the occurrence of an unforeseen developmentthat occurred after the agreement was signed. The termination of this merger agreement between Sciele and Victory will have aminimal impact on Shionogi, and it is expected to have a small impact onSciele`s 2009 revenue and earnings guidance. ATLANTA--(Business Wire)--Sciele Pharma, Inc. (Head Office: Atlanta, Georgia, USA; CEO and Chairman:Patrick P. Fourteau; hereafter "Sciele"), a U.S.-based group company of Shionogi& Co., Ltd.